PKM2 subcellular localization is involved in oxaliplatin resistance acquisition in human colorectal cancer cell lines

被引：0
|
作者：
Gines, Alba [1 ]
Martinez-Cardus, Anna [2 ]
Ruiz de Porras, Vicenc [1 ]
Musulen, Eva [3 ]
Luis Manzano, Jose [1 ,4 ]
Layos, Laura [1 ,4 ]
Buges, Cristina [1 ,4 ]
Abad, Albert [5 ]
Martinez-Balibrea, Eva [1 ,4 ]
机构：
[1] Germans Trias & Pujol Fdn IGTP, Hlth Sci Res Inst, Badalona, Spain
[2] Bellvitge Biomed Res Inst IDIBELL, PEBC, Lhospitalet De Llobregat, Barcelona, Spain
[3] Univ Hosp Germans Trias & Pujol, Human Pathol Dept, Badalona, Spain
[4] Germans Trias & Pujol Fdn IGTP, Catalan Inst Oncol, Badalona, Spain
[5] UCCO, Oncol Serv, Barcelona, Spain
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-3752
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3752
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines
    Gines, Alba
    Bystrup, Sara
    Ruiz de Porras, Vicenc
    Guardia, Cristina
    Musulen, Eva
    Martinez-Cardus, Anna
    Luis Manzano, Jose
    Layos, Laura
    Abad, Albert
    Martinez-Balibrea, Eva
    PLOS ONE, 2015, 10 (05):
  • [2] PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer
    Sfakianaki, M.
    Papadaki, C.
    Tzardi, M.
    Trypaki, M.
    Manolakou, S.
    Messaritakis, I.
    Saridaki, Z.
    Mavroudis, D.
    Georgoulias, V.
    Souglakos, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
    Sfakianaki, Maria
    Papadaki, Chara
    Tzardi, Maria
    Trypaki, Maria
    Manolakou, Stavroula
    Messaritakis, Ippokratis
    Saridaki, Zenia
    Athanasakis, Elias
    Mavroudis, Dimitrios
    Tsiaoussis, John
    Gouvas, Nikolaos
    Souglakos, John
    CANCERS, 2020, 12 (08) : 1 - 14
  • [4] Efficacy and mechanism of combination of oxaliplatin with PKM2 knockdown in colorectal cancer
    Yin, Chenxi
    Lu, Wenhua
    Ma, Mingzhe
    Yang, Qiong
    He, Wenzhuo
    Hu, Yumin
    Xia, Liangping
    ONCOLOGY LETTERS, 2020, 20 (06)
  • [5] Different mechanism of Oxaliplatin resistance in human colorectal cancer cell lines
    Yamano, Tomoki
    Kubo, Shuji
    Yano, Aya
    Tomita, Naohiro
    CANCER RESEARCH, 2015, 75
  • [6] Scutellarin resensitizes oxaliplatin-resistant colorectal cancer cells to oxaliplatin treatment through inhibition of PKM2
    Sun, Wei
    Ge, Yang
    Cui, Junpeng
    Yu, Yifan
    Liu, Baolin
    MOLECULAR THERAPY-ONCOLYTICS, 2021, 21 : 87 - 97
  • [7] PKM2 as a biomarker for sensitivity to oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC).
    Papadaki, C.
    Saridaki, Z.
    Tzardi, M.
    Sfakianaki, M.
    Sfakiotaki, G.
    Trypaki, M.
    Messaritakis, I.
    Mavroudis, D.
    Georgoulias, V.
    Sougklakos, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [8] Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells
    Lu, Wei-Qun
    Hu, Ying-Ying
    Lin, Xiao-Ping
    Fan, Wei
    ONCOTARGET, 2017, 8 (27) : 44171 - 44185
  • [9] PKM2 and HIF-1α regulation in prostate cancer cell lines
    Hasan, Diya
    Gamen, Elisabetta
    Abu Tarboush, Nafez
    Ismail, Yazan
    Pak, Oleg
    Azab, Belal
    PLOS ONE, 2018, 13 (09):
  • [10] Coexisting Molecular Determinants of Acquired Oxaliplatin Resistance in Human Colorectal and Ovarian Cancer Cell Lines
    Noordhuis, Paul
    Laan, Adrianus C.
    van de Born, Kasper
    Honeywell, Richard J.
    Peters, Godefridus J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (15)
12345